Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Refill Reminder Programs May Be Next Free Speech Battleground For Pharma

This article was originally published in The Pink Sheet Daily

Executive Summary

Adheris sues HHS, arguing rule requiring patient authorization of Rx refill reminders violates its First Amendment rights; complaint may test scope of Supreme Court’s Sorrell ruling.

You may also be interested in...



Medication Adherence: A Positive Story You Are Not Hearing

Pharmaceutical companies are spending more to help patients adhere to their therapeutic regimens – an almost universally recognized way to improve health outcomes and pharma’s bottom line. But an unclear legal and regulatory climate and poor understanding of the adherence problems it is trying to solve means industry isn’t trumpeting what could be one of its best health care value arguments.

Rx Data Mining Opponents Will Need New Pitch After Supreme Court Strikes Down Vermont Law

The court affirms the Second Circuit's ruling that a Vermont statute prohibiting drug companies from using Rx data to market to doctors imposes an impermissible restriction on free speech.

Gilead Wins Breach Of Contract Suit Against CDC But Damages, Patent Dispute Are Unresolved

Court finds government failed to promptly notify Gilead of its PrEP-related patent applications as required under agreements for supply of HIV drugs used in CDC studies. Whether Gilead will have to license government patents remains undecided.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS076343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel